Vectus Biosystems Limited (ASX:VBS)
Australia · Delayed Price · Currency is AUD 0.1400
0.00 (0.00%)
Jan 30, 2026, 10:03 AM AEST
Vectus Biosystems Company Description
Vectus Biosystems Limited engages in the medical research and development activities in Australia.
The company develops treatment for cardiovascular fibrosis and systolic blood pressure, as well as treatments for cardiac fibrosis, kidney, liver, and lung fibrosis.
Its lead compound is VB0004, currently under phase Ib clinical human trial, which is aimed at treating the loss of functional tissue to fibrosis, and scarring.
The company also intends to develop candidates for the treatment of fibrotic liver diseases, including non-alcoholic steatohepatitis and pulmonary fibrotic diseases.
The company was incorporated in 2005 and is based in Rosebery, Australia.
Vectus Biosystems Limited
| Country | Australia |
| Founded | 2005 |
| Industry | Biotechnology |
| Sector | Healthcare |
Contact Details
Address: 26-34 Dunning Avenue Rosebery, NSW 2018 Australia | |
| Phone | 61 2 8344 1300 |
| Website | vectusbiosystems.com.au |
Stock Details
| Ticker Symbol | VBS |
| Exchange | Australian Securities Exchange |
| Fiscal Year | July - June |
| Reporting Currency | AUD |
| ISIN Number | AU000000VBS9 |
| SIC Code | 2836 |
Key Executives
| Name | Position |
|---|---|
| Dr. Ivan Rajkovic Ph.D. | Interim Chief Technology Officer |
| Robert John Waring BEc, CA, FAICD, FCIS, FFin | Company Secretary |
| Prof. Graham Jon MacDonald AM, BS, BSc (Med), FANZCC, FRACP, FRCP, M.D. | Consultant |